Research graph
References from Decisions in Diuretic Resistance: Oral or Subcutaneous Furosemide in Advanced Ambulatory Heart Failure?. Local targets link to admitted publications; unresolved targets remain external evidence.
2021 ESC Guidelines for the diagnosis treatment of acute chronic heart failure
10.1093/eurheartj/ehab368 · 2021 · External reference
Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.1236 · 2018 · External reference
A 2018 overview of diuretic resistance in heart failure
10.1016/j.repc.2018.03.014 · 2018 · External reference
Diuretic resistance in acute heart failure: Proposal for a new urinary sodium-based definition
10.1016/j.ijcard.2024.132456 · 2024 · External reference
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure
10.1161/hypertensionaha.120.15205 · 2020 · External reference
Peripheral access ultrafiltration as a treatment for cardiorenal syndrome with inadequate diuretic response. Initial experience
2023 · External reference
Therapeutic approach in heart failure with poor diuretic response: Peripheral ultrafiltration vs. conventional treatment
10.1002/ehf2.14386 · 2023 · External reference
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review
10.1002/ehf2.15125 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Administration of Subcutaneous Furosemide in Elastomeric Pump vs. Oral Solution for the Treatment of Diuretic Refractory Congestion
10.1007/s40292-021-00476-4 · 2021 · External reference
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
2022 · External reference
The use of diuretics in heart failure with congestion—A position statement from the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.1369 · 2019 · External reference
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure
10.1016/j.jacc.2008.05.068 · 2009 · External reference
Diuretics in the management of chronic heart failure: When and how
10.18773/austprescr.2022.069 · 2022 · External reference
Furosemide absorption altered in decompensated congestive heart failure
10.7326/0003-4819-102-3-314 · 1985 · External reference
A reappraisal of loop diuretic choice in heart failure patients
10.1016/j.ahj.2014.12.009 · 2015 · External reference
Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution
10.1016/j.jacbts.2017.10.001 · 2018 · External reference
Subcutaneous furosemide in heart failure: A systematic review
10.1093/ehjcvp/pvae083 · 2025 · External reference
Human Factors Validation of a Wearable, On-Body Infusor for Subcutaneous Administration of Furosemide
2024 · External reference
Outpatient Intravenous Diuretic Clinic: An Effective Strategy for Management of Volume Overload and Reducing Immediate Hospital Admissions
10.14740/jocmr4499 · 2021 · External reference
Avoiding Treatment in Hospital with Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)
10.1016/j.jchf.2024.07.015 · 2024 · External reference
Prognostic implications of hypo and hyperkalaemia in acute heart failure with reduced ejection fraction. Analysis of cardiovascular mortality and hospital readmissions
2022 · External reference
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload
10.1056/nejmoa2203094 · 2022 · External reference
Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial
10.1001/jama.297.12.1319 · 2007 · External reference
Use of tolvaptan in patients with hyponatremia due to heart failure: Initial experience
2013 · External reference
Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry
10.1016/j.jacc.2018.04.070 · 2018 · External reference
Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction
10.1007/s00392-023-02241-0 · 2024 · External reference
Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: A Real-World Study
10.1007/s12265-021-10173-1 · 2022 · External reference
Interpretation and use of natriuretic peptides in non-congestive heart failure settings
10.3349/ymj.2010.51.2.151 · 2010 · External reference
Ambulatory intravenous treatment of decompensated heart failure: An effective, safe and cost-effective approach
10.1016/j.rccl.2020.05.009 · 2021 · External reference
Diuretic Therapy for Patients with Heart Failure: JACC State-of-the-Art Review
10.1016/j.jacc.2019.12.059 · 2020 · External reference
From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion
10.1016/j.shj.2022.100076 · 2022 · External reference
Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States
10.1016/j.jacc.2018.12.034 · 2019 · External reference
Ambulatory intravenous furosemide for decompensated heart failure: Safe, feasible, and effective
10.1002/ehf2.13368 · 2021 · External reference
Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling
10.1002/ejhf.3131 · 2024 · External reference
Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial
10.1001/jama.297.12.1319 · ExternalCitation · doi-reference
Ambulatory intravenous furosemide for decompensated heart failure: Safe, feasible, and effective
10.1002/ehf2.13368 · ExternalCitation · doi-reference
Therapeutic approach in heart failure with poor diuretic response: Peripheral ultrafiltration vs. conventional treatment
10.1002/ehf2.14386 · ExternalCitation · doi-reference
Analysis of the usefulness and benefits of ultrafiltration in cardiorenal syndrome: A systematic review
10.1002/ehf2.15125 · ExternalCitation · doi-reference
Advanced heart failure: A position statement of the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.1236 · ExternalCitation · doi-reference
The use of diuretics in heart failure with congestion—A position statement from the Heart Failure Association of the European Society of Cardiology
10.1002/ejhf.1369 · ExternalCitation · doi-reference
Sodium loading in ambulatory patients with heart failure with reduced ejection fraction: Mechanistic insights into sodium handling
10.1002/ejhf.3131 · ExternalCitation · doi-reference
Influence of the medical treatment schedule in new diagnoses patients with heart failure and reduced ejection fraction
10.1007/s00392-023-02241-0 · ExternalCitation · doi-reference
Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: A Real-World Study
10.1007/s12265-021-10173-1 · ExternalCitation · doi-reference
Administration of Subcutaneous Furosemide in Elastomeric Pump vs. Oral Solution for the Treatment of Diuretic Refractory Congestion
10.1007/s40292-021-00476-4 · ExternalCitation · doi-reference
A reappraisal of loop diuretic choice in heart failure patients
10.1016/j.ahj.2014.12.009 · ExternalCitation · doi-reference
Diuretic resistance in acute heart failure: Proposal for a new urinary sodium-based definition
10.1016/j.ijcard.2024.132456 · ExternalCitation · doi-reference
Subcutaneous Furosemide in Heart Failure: Pharmacokinetic Characteristics of a Newly Buffered Solution
10.1016/j.jacbts.2017.10.001 · ExternalCitation · doi-reference
Importance of venous congestion for worsening of renal function in advanced decompensated heart failure
10.1016/j.jacc.2008.05.068 · ExternalCitation · doi-reference
Medical Therapy for Heart Failure with Reduced Ejection Fraction: The CHAMP-HF Registry
10.1016/j.jacc.2018.04.070 · ExternalCitation · doi-reference
Outpatient Intravenous Diuretic Therapy for Heart Failure in the United States
10.1016/j.jacc.2018.12.034 · ExternalCitation · doi-reference
Diuretic Therapy for Patients with Heart Failure: JACC State-of-the-Art Review
10.1016/j.jacc.2019.12.059 · ExternalCitation · doi-reference
Avoiding Treatment in Hospital with Subcutaneous Furosemide for Worsening Heart Failure: A Pilot Study (AT HOME-HF)
10.1016/j.jchf.2024.07.015 · ExternalCitation · doi-reference
Ambulatory intravenous treatment of decompensated heart failure: An effective, safe and cost-effective approach
10.1016/j.rccl.2020.05.009 · ExternalCitation · doi-reference
A 2018 overview of diuretic resistance in heart failure
10.1016/j.repc.2018.03.014 · ExternalCitation · doi-reference
From Oral to Subcutaneous Furosemide: The Road to Novel Opportunities to Manage Congestion
10.1016/j.shj.2022.100076 · ExternalCitation · doi-reference
Acetazolamide in Acute Decompensated Heart Failure with Volume Overload
10.1056/nejmoa2203094 · ExternalCitation · doi-reference
Subcutaneous furosemide in heart failure: A systematic review
10.1093/ehjcvp/pvae083 · ExternalCitation · doi-reference
2021 ESC Guidelines for the diagnosis treatment of acute chronic heart failure
10.1093/eurheartj/ehab368 · ExternalCitation · doi-reference
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure
10.1161/hypertensionaha.120.15205 · ExternalCitation · doi-reference
Outpatient Intravenous Diuretic Clinic: An Effective Strategy for Management of Volume Overload and Reducing Immediate Hospital Admissions
10.14740/jocmr4499 · ExternalCitation · doi-reference
Diuretics in the management of chronic heart failure: When and how
10.18773/austprescr.2022.069 · ExternalCitation · doi-reference
Interpretation and use of natriuretic peptides in non-congestive heart failure settings
10.3349/ymj.2010.51.2.151 · ExternalCitation · doi-reference
Furosemide absorption altered in decompensated congestive heart failure
10.7326/0003-4819-102-3-314 · ExternalCitation · doi-reference
